Effects of bevacizumab plus chemotherapy on serum tumor markers and serum levels of transforming growth factor-β1,Smad-3 and Smad-7 in advanced colorectal cancer
OBJECTIVE To explore the effects of bevacizumab plus chemotherapy on serum tumor markers and serum lev-els of transforming growth factor-beta 1(TGF-β1),Smad-3 and Smad-7 in advanced colorectal cancer(CRC).METHODS A total of 62 CRC patients hospitalized from November 2020 to November 2021 at Fourth Municipal People's Hospital,and fol-lowed up until December 2023 were randomized into two groups of control(receiving FOLFOX6 chemotherapy)and observation(receiving bevacizumab plus FOLFOX6 chemotherapy)(n=31 each).Fourteen days were counted as one cycle and treatment lasted for four cycles in two groups.After the end of treatment course,all patients were followed up for 2 years.Recent and long-term clinical efficacy,serum levels of tumor markers,TGF-β1,Smad-3,Smad-7,as well as adverse reactions before and after treatment for four cycles were compared between two groups.RESULTS After 4 cycles of treatment,objective remission rate and disease control rate of observation group were significantly higher than those of control group(P＜0.05).After 2-year follow-ups,progression-free survival(PFS)and overall survival(OS)of observation group were longer than those of control group while recurrence rate and mortality were lower than those of control group(P＜0.05).After 4 cycles of treatment,serum levels of carbohydrate antigen 125,cytokeratin 19 fragment antigen 21-1,carcinoembryonic antigen,TGF-β1 and Smad-3 were lower in observation group than those in control group while the level of Smad-7 was higher than that in control group(P＜0.05).No significant inter-group difference existed in overall incidence of adverse reactions(x2=1.620,P=0.203).CONCLUSION Beva-cizumab plus FOLFOX6 chemotherapy for advanced CRC may facilitate regulating serum levels of tumor markers,TGF-β1,Smad-3 and Smad-7.
NETL
NSTL
万方数据
